1 day Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?The Motley Fool
This clinical-stage drugmaker’s AI platform could speed up the development process, but initial results were disappointing.
AI · Nasdaq 100 · Pharmaceuticals · Tech
X